250 related articles for article (PubMed ID: 21257648)
1. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?
Herbild L; Bech M; Gyrd-Hansen D; Christensen M; Werge T; Nielsen KA
Scand J Public Health; 2011 Mar; 39(2):147-55. PubMed ID: 21257648
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings.
Fagerness J; Fonseca E; Hess GP; Scott R; Gardner KR; Koffler M; Fava M; Perlis R; Brennan FX; Lombard J
Am J Manag Care; 2014 May; 20(5):e146-56. PubMed ID: 25326929
[TBL] [Abstract][Full Text] [Related]
3. Is pharmacogenetic CYP2D6 testing useful?
Vetti HH; Molven A; Eliassen AK; Steen VM
Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
[TBL] [Abstract][Full Text] [Related]
4. Nurses' genetic/genomics competencies when medication therapy is guided by pharmacogenetic testing: children with mental health disorders as an exemplar.
Prows CA; Saldaña SN
J Pediatr Nurs; 2009 Jun; 24(3):179-88. PubMed ID: 19467430
[TBL] [Abstract][Full Text] [Related]
5. Current applications of clinical genetic testing for psychiatric practice.
Mrazek DA
Minn Med; 2007 Jan; 90(1):42-3. PubMed ID: 17305105
[TBL] [Abstract][Full Text] [Related]
6. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic monitoring of psychotropic drugs and pharmacogenetic tests in psychiatry].
Voirol P; Eap CB; Baumann P
Rev Med Suisse Romande; 2000 Feb; 120(2):99-104. PubMed ID: 10748694
[No Abstract] [Full Text] [Related]
8. Pharmacogenetic considerations in the treatment of psychiatric disorders.
Lohoff FW; Ferraro TN
Expert Opin Pharmacother; 2010 Feb; 11(3):423-39. PubMed ID: 20102306
[TBL] [Abstract][Full Text] [Related]
9. Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
Preskorn SH
J Psychiatr Pract; 2010 May; 16(3):177-82. PubMed ID: 20485106
[TBL] [Abstract][Full Text] [Related]
10. Regional variations and determinants of direct psychiatric costs in Sweden.
Tiainen A; Edman G; Flyckt L; Tomson G; Rehnberg C
Scand J Public Health; 2008 Jul; 36(5):483-92. PubMed ID: 18635731
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Psychiatric Practice Guidelines on Medication Costs and Youth Aggression in a Juvenile Justice Residential Treatment Program.
Lee TG; Walker SC; Bishop AS
Psychiatr Serv; 2016 Feb; 67(2):214-20. PubMed ID: 26423102
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacogenetics/pharmacogenomics in psychiatry].
Ueda M; Ishiguro S; Watanabe T; Saeki Y; Shimoda K
Nihon Rinsho; 2010 Jan; 68(1):155-62. PubMed ID: 20077810
[TBL] [Abstract][Full Text] [Related]
13. Economic Utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Health Care in a Primary Care Setting.
Brown LC; Lorenz RA; Li J; Dechairo BM
Clin Ther; 2017 Mar; 39(3):592-602.e1. PubMed ID: 28238356
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of pharmacogenetics in psychiatry].
Skrętkowicz J; Barańska M; Rychlik-Sych M
Wiad Lek; 2013; 66(2 Pt 2):185-91. PubMed ID: 25775815
[TBL] [Abstract][Full Text] [Related]
15. Where are we today with personalized medicine?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2012 Nov; 50(11):11-3. PubMed ID: 23066831
[TBL] [Abstract][Full Text] [Related]
16. Personalized pharmacotherapy in psychiatry.
Filaković P; Petek A
Psychiatr Danub; 2009 Sep; 21(3):341-6. PubMed ID: 19794353
[TBL] [Abstract][Full Text] [Related]
17. Examination of the effects of financial risk on the formal treatment costs for a Medicaid population with psychiatric disabilities.
Jones K; Chen HJ; Jordan N; Boothroyd RA; Ramoni-Perazzi J; Shern DL
Med Care; 2006 Apr; 44(4):320-7. PubMed ID: 16565632
[TBL] [Abstract][Full Text] [Related]
18. Trends in mental health cost growth: an expanded role for management?
Frank RG; Goldman HH; McGuire TG
Health Aff (Millwood); 2009; 28(3):649-59. PubMed ID: 19414870
[TBL] [Abstract][Full Text] [Related]
19. Reconceptualizing medication adherence: six phases of dynamic adherence.
Gearing RE; Townsend L; MacKenzie M; Charach A
Harv Rev Psychiatry; 2011; 19(4):177-89. PubMed ID: 21790266
[TBL] [Abstract][Full Text] [Related]
20. Psychopharmacology: the need for effectiveness trials to inform evidence-based psychiatric practice.
Lagomasino IT; Dwight-Johnson M; Simpson GM
Psychiatr Serv; 2005 Jun; 56(6):649-51. PubMed ID: 15939939
[No Abstract] [Full Text] [Related]
[Next] [New Search]
